Skip to Content

Callitas Health Inc MPHMF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Callitas Health Inc is a clinical-stage company. It is engaged in developing technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The company's products offering includes ToConceive, C-103 Reformulated Orlistat, and Extrinsa. ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman's own natural conception lubrication, called transudate, to aid in conception. Orlistat is FDA-approved for weight management and sold by Roche as Xenical (prescription) and by GlaxoSmithKline as alli. Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and the non-systemic product is also non-hormonal and does not affect the central nervous system.

Contact
734 - 1055 Dunsmuir Street
Vancouver, BC, V7X 1B1, Canada
T +1 201 736-3590
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees